• Company
• RET-targeted Retevmo lands in general hospitals in KOR
• by Eo, Yun-Ho Jan 13, 2023 06:02am

• Policy
• Dupxient deemed adequate for reimb in children with AD
• by Lee, Tak-Sun Jan 13, 2023 06:01am

• Opinion
• [Reporter's view] The Pharmaceutical Bio-Innovation Committe
• by Kim, Jin-Gu Jan 13, 2023 06:01am

• Policy
• Lee Jong-sung, who pointed out Moon Care
• by Lee, Jeong-Hwan Jan 13, 2023 06:01am

• Company
• GC Pharma exclusively distributes and sells Baraclude
• by Kim, Jin-Gu Jan 13, 2023 06:01am

• Company
• Baxter's core business unit spun off
• by jung, sae-im Jan 12, 2023 04:32am

• Company
• Celltrion launches Stella PO development with U.S. Rani
• by Jan 12, 2023 04:30am

• Company
• 80 companies participated in the K-Cab patent dispute
• by Kim, Jin-Gu Jan 12, 2023 04:30am

• Policy
• Sama Pharm’s formoterol to receive clinical reevaluations
• by Lee, Hye-Kyung Jan 12, 2023 04:29am

• Company
• Dupixent to be reviewed by DREC for reimb after 2 years
• by Eo, Yun-Ho Jan 12, 2023 04:29am